H.C. Wainwright raised the firm’s price target on Fate Therapeutics (FATE) to $7 from $5 and keeps a Buy rating on the shares. The firm says FT819 continues to demonstrate meaningful reductions in systemic lupus erythematosus disease activity.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FATE: